Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 October 2020Website:
http://foghorntx.comNext earnings report:
01 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 30 Sep 2024 20:03:13 GMTDividend
Analysts recommendations
Institutional Ownership
FHTX Latest News
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
The consensus price target hints at a 121.8% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.70 per share a year ago.
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies Global Healthcare Conference and the Goldman Sachs 45th Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Positions company to further leverage strength of platform and advance programs through multiple data readouts and clinical value inflection points
Foghorn Therapeutics Inc. (FHTX) reported a quarterly loss of $0.59 per share, slightly higher than the Zacks Consensus Estimate of a loss of $0.55 per share. This is an improvement from the loss of $0.73 per share reported a year ago.
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 1(current)
What type of business is Foghorn Therapeutics?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is Foghorn Therapeutics in?
Foghorn Therapeutics is in the Healthcare sector
What industry is Foghorn Therapeutics in?
Foghorn Therapeutics is in the Biotechnology industry
What country is Foghorn Therapeutics from?
Foghorn Therapeutics is headquartered in United States
When did Foghorn Therapeutics go public?
Foghorn Therapeutics initial public offering (IPO) was on 23 October 2020
What is Foghorn Therapeutics website?
https://foghorntx.com
Is Foghorn Therapeutics in the S&P 500?
No, Foghorn Therapeutics is not included in the S&P 500 index
Is Foghorn Therapeutics in the NASDAQ 100?
No, Foghorn Therapeutics is not included in the NASDAQ 100 index
Is Foghorn Therapeutics in the Dow Jones?
No, Foghorn Therapeutics is not included in the Dow Jones index
When was Foghorn Therapeutics the previous earnings report?
No data
When does Foghorn Therapeutics earnings report?
The next expected earnings date for Foghorn Therapeutics is 01 November 2024